Premium
Cellular immune recognition of HLA‐G‐expressing choriocarcinoma cell line JEG‐3
Author(s) -
Burt Deborah,
Johnston Diane,
de Wit Tobias Rinke,
van den Elsen Peter,
Stern Peter L.
Publication year - 1991
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910470722
Subject(s) - choriocarcinoma , trophoblast , biology , immune system , major histocompatibility complex , ctl* , mhc class i , human leukocyte antigen , immunology , priming (agriculture) , cytotoxic t cell , microbiology and biotechnology , cancer research , antigen , fetus , cd8 , in vitro , genetics , placenta , pregnancy , germination , botany
Jeg‐3 choriocarcinoma cells express class‐I MHC HLA‐G and low levels of a novel HLA‐C product. The functional significance of such novel MHC class‐I expression in regard of the cellular immune response has been investigated. Jeg‐3 cells are NK‐insensitive, but susceptible to LAK cytotoxicity, some of which is mediated by T cells. No Jeg‐3‐specific CTL or proliferative responses could be generated in allogeneic responder PBMC from several different donors. There was no detectable xenogeneic recognition of Jeg‐3 cells even when preceded by in vivo priming. Jeg‐3 cells are able to suppress proliferative responses in humans and others species. This is not reproduced by conditioned medium from the Jeg‐3 cells, but can be overridden by IL‐2. The ability of the Jeg‐3 choriocarcinoma (trophoblast) cells to suppress in the MLR may reflect the processes which are shared to enable the survival of the foetus in a semi‐allogeneic mother or a tumour in its host. It is not clear whether there is any relationship between the unusual class‐I‐MHC expression by trophoblast and the putative regulatory properties of the latter.